202 related articles for article (PubMed ID: 23303813)
1. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis.
Ben-Ami R; Albert ND; Lewis RE; Kontoyiannis DP
J Infect Dis; 2013 Apr; 207(7):1066-74. PubMed ID: 23303813
[TBL] [Abstract][Full Text] [Related]
2. Enhancing angiogenesis in invasive aspergillosis: a novel therapeutic approach.
Ito JI
J Infect Dis; 2013 Apr; 207(7):1031-3. PubMed ID: 23303815
[No Abstract] [Full Text] [Related]
3. Efficacy of ambruticin analogs in a murine model of invasive pulmonary aspergillosis.
Chiang LY; Ejzykowicz DE; Tian ZQ; Katz L; Filler SG
Antimicrob Agents Chemother; 2006 Oct; 50(10):3464-6. PubMed ID: 17005833
[TBL] [Abstract][Full Text] [Related]
4. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Prince RA; Chi J; Kontoyiannis DP
Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
[TBL] [Abstract][Full Text] [Related]
6. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
Manavathu EK; Cutright JL; Chandrasekar PH
Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
[TBL] [Abstract][Full Text] [Related]
7. Standardization of an experimental murine model of invasive pulmonary aspergillosis.
Sheppard DC; Graybill JR; Najvar LK; Chiang LY; Doedt T; Kirkpatrick WR; Bocanegra R; Vallor AC; Patterson TF; Filler SG
Antimicrob Agents Chemother; 2006 Oct; 50(10):3501-3. PubMed ID: 17005844
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.
Chandrasekar PH; Cutright JL; Manavathu EK
Clin Microbiol Infect; 2004 Oct; 10(10):925-8. PubMed ID: 15373889
[TBL] [Abstract][Full Text] [Related]
9. SCH56592 treatment of murine invasive aspergillosis.
Graybill JR; Bocanegra R; Najvar LK; Luther MF; Loebenberg D
J Antimicrob Chemother; 1998 Oct; 42(4):539-42. PubMed ID: 9818757
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
Chandrasekar PH; Cutright J; Manavathu E
J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
[TBL] [Abstract][Full Text] [Related]
11. Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis.
Rieg G; Spellberg B; Schwartz J; Fu Y; Edwards JE; Sheppard DC; Ibrahim AS
Antimicrob Agents Chemother; 2006 Aug; 50(8):2895-6. PubMed ID: 16870798
[No Abstract] [Full Text] [Related]
12. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
Allendoerfer R; Loebenberg D; Rinaldi MG; Graybill JR
Antimicrob Agents Chemother; 1995 Jun; 39(6):1345-8. PubMed ID: 7574528
[TBL] [Abstract][Full Text] [Related]
13. Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis.
Kaur S; Gupta VK; Thiel S; Sarma PU; Madan T
Clin Exp Immunol; 2007 May; 148(2):382-9. PubMed ID: 17335555
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis.
Denning DW; Hall L; Jackson M; Hollis S
Antimicrob Agents Chemother; 1995 Aug; 39(8):1809-14. PubMed ID: 7486923
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis.
Gavaldà J; Martín MT; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruíz I; Pahissa A
Antimicrob Agents Chemother; 2005 Jul; 49(7):3028-30. PubMed ID: 15980392
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.
Matsumoto S; Wakai Y; Nakai T; Hatano K; Ushitani T; Ikeda F; Tawara S; Goto T; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Mar; 44(3):619-21. PubMed ID: 10681328
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.
Defaveri J; Salazar MH; Rinaldi MG; Graybill JR
Am Rev Respir Dis; 1990 Sep; 142(3):512-5. PubMed ID: 2202244
[TBL] [Abstract][Full Text] [Related]
18. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
19. In vivo evaluation of the antifungal activity of sertraline against Aspergillus fumigatus.
Treviño-Rangel RJ; Villanueva-Lozano H; Méndez-Galomo KS; Solís-Villegas EM; Becerril-García MA; Montoya AM; Robledo-Leal ER; González GM
J Antimicrob Chemother; 2019 Mar; 74(3):663-666. PubMed ID: 30403787
[TBL] [Abstract][Full Text] [Related]
20. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.
Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]